Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
RANI
Strong SellSinkerRani Therapeutics Holdings, Inc. · Healthcare · United States · $118M · Avg Vol: $512K/d
7
StockRankGet insider-trade alerts
Q
27
V
28
M
21
P/E (TTM)
—
ROE
-172.1%
D/E
0.1x
Dividend %
—
COMPANY DESCRIPTION
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 1.0M | 1.6M | 58.9% | 4.9M | 6.3M | 6.6M | 101.5% |
| EPS | -0.29 | -0.31 | -0.31 | -0.45 | — | -0.13 | -0.17 | -0.19 | — |
| Shares | 112.4M | 112.4M | 112.4M | 97.6M | -13.1% | 115.4M | — | — | — |
| Debt | 30.2M | 30.1M | 29.7M | 4.3M | -47.7% | 3.5M | — | — | — |
| Equity | 36.9M | 12.9M | 2.0M | 33.0M | -3.6% | — | — | — | — |
| Op CF | -46.5M | -51.2M | -35.5M | -18.7M | — | -20.3M | — | — | — |
| Inv CF | -72.4M | 29.9M | 19.8M | -7.0M | — | — | — | — | — |
| Fin CF | 29.0M | 0.2M | 13.6M | 40.3M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+0.2%
SMA 50SMA 200
Close
$0.822
RSI (14)
43.7
52W High
$3.87
From 52W High
0.2%
SCORE BREAKDOWN
Quality
27
ROIC
-74.4%9.8
ROE
-172.1%5.3
GP/Assets
8.3%23.0
Op. Margin
-516.9%10.1
FCF/Assets
-32.1%12.1
Piotroski
559.7
Int. Cover
-16.8x18.4
D/E Ratio
0.07x66.6
Current Ratio
5.31x73.8
Value
28
P/E (TTM)
—N/A
EV/EBITDA
-1.8x25.0
P/FCF
—N/A
P/B
2.5x53.8
P/S
24.9x13.9
Div Yield
—N/A
Momentum
21
52W High %
21%3.8
RS 6M
-53%11.7
SMA 50/200
0.75x10.9
EPS Rev 4W
+10.9%90.2
EPS Rev 12W
—N/A
EPS Improve
-46%9.9
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$118M
P/E (Forward)
-4.6x
Gross Margin
100.0%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of RANI are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| RANI | Rani Therapeutics Holdings, Inc.(you) | $118M | 7 | Strong Sell |
| GNLX | Genelux Corporation | $120M | 4 | Strong Sell |
| ONCY | Oncolytics Biotech Inc. | $109M | 5 | Strong Sell |
| HURA | TuHURA Biosciences, Inc. | $134M | 6 | Strong Sell |
| VRCA | Verrica Pharmaceuticals Inc. | $98M | 7 | Strong Sell |
| NAUT | Nautilus Biotechnology, Inc. | $113M | 4 | Strong Sell |
| KLRS | Kalaris Therapeutics, Inc. | $96M | 7 | Strong Sell |
| COYA | Coya Therapeutics, Inc. | $108M | 10 | Strong Sell |
| PLYX | Polaryx Therapeutics, Inc. | $103M | 5 | Strong Sell |
| VANI | Vivani Medical, Inc. | $128M | 11 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.1%